

PLEASE AMEND THIS APPLICATION AS FOLLOWS:

In The Title:

Change the title to:

-- MULTIMERIC COMPLEX COMPOSITIONS AND DELIVERY PROCESSES
USING SAME --.

In the Claims:

Cancel claim 1.

Add new claims 245-279 as follows:

-- 245. (NEW) A multimeric complex composition comprising more than one monomeric unit attached, :

- (a) to each other through polymeric interactions, or
- (b) to a binding matrix through polymeric interactions, or
- (c) both (a) and (b). --

-- 246. (NEW) The composition of claim 245, wherein the polymer or oligomer of said monomeric unit is linear or branched. --

-- 247. (NEW) The composition of claim 245, wherein the polymer or oligomer of said monomeric unit comprises of homopolymer or heteropolymer. --

-- 248. (NEW) The composition of claim 245, wherein said monomeric unit comprises an analyte-specific moiety. --

-- 249. (NEW) The composition of claim 248, wherein said analyte-specific moiety is capable of recognizing a component in a biological system. --

-- 250. (NEW) The composition of claim 249, wherein said biological system is selected from a virus, a phage, a bacterium, a cell or cellular material, a tissue, an organ and an organism, or a combination thereof. --

-- 251. (NEW) The composition of claim 245, wherein said monomeric unit is selected from a naturally occurring compound, a modified natural compound, a synthetic compound and a recombinantly produced compound, or a combination thereof. --

BEST AVAILABLE COPY

-- 252. (NEW) The composition of claim 245, wherein said analyte-specific moiety is derived or selected from a protein, a polysaccharide, a fatty acid or fatty acid ester and a polynucleotide, or a combination of the foregoing. --

-- 253. (NEW) The composition of claim 252, wherein said protein is selected from an antibody, a hormone, a growth factor, a lymphokine or cytokine and a cellular matrix protein, or a combination of any of the foregoing. --

-- 254. (NEW) The composition of claim 253, wherein said antibody comprises a polyclonal or monoclonal antibody. --

-- 255. (NEW) The composition of claim 252, wherein said polynucleotide is linear or circular. --

-- 256. (NEW) The composition of claim 252, wherein said polynucleotide is single stranded. --

-- 257. (NEW) The composition of claim 245, wherein the polymer or oligomer of said binding matrix is linear or branched. --

-- 258. (NEW) The composition of claim 245, wherein the polymer or oligomer of said binding matrix comprises a homopolymer or heteropolymer. --

-- 259. (NEW) The composition of claim 245, wherein said binding matrix is selected from a naturally occurring compound, a modified natural compound, a synthetic compound and a recombinantly produced compound, or a combination thereof. --

-- 260. (NEW) The composition of claim 245, wherein said binding matrix comprises a member selected from a polypeptide, a polynucleotide and a polysaccharide, or a combination thereof. --

-- 261. (NEW) The composition of claim 245, wherein said polymeric interactions are selected from ionic interactions, hydrogen bonding, dipole-dipole interactions, or a combination of the foregoing. --

Sub
D4
Cont

-- 262. (NEW) The composition of claim 261, wherein said ionic interactions comprise polycationic interactions or polycationic interactions. --

-- 263. (NEW) The composition of claim 245, further comprising an entity attached to said binding matrix. --

-- 264. (NEW) The composition of claim 263, wherein said entity comprises a ligand or a compound which increases binding of the binding matrix. --

-- 265. (NEW) The composition of claim 245, in homogeneous form. --

-- 266. (NEW) The composition of claim 245, in heterogeneous form. --

-- 267. (NEW) A process for delivering a cell effector to a cell, comprising: providing the multimeric complex composition of claim 245 wherein said monomeric unit comprises said cell effector; and administering said composition. --

-- 268. (NEW) The process of claim 267, wherein said composition is delivered *in vivo*. --

-- 269. (NEW) The process of claim 267, wherein said composition is delivered *ex vivo*. --

-- 270. (NEW) The process of claim 267, wherein said cell is contained in an organism. --

-- 271. (NEW) A process for delivering a gene or fragment thereof to a cell, comprising:
providing the multimeric complex composition of claim 245, wherein said monomeric unit comprises said gene or gene fragment; and administering said composition. --

-- 272. (NEW) The process of claim 271, wherein said composition is delivered *in vivo*. --

BEST AVAILABLE COPY

-- 273. (NEW) The process of claim 271, wherein said composition is delivered *ex vivo*. --

-- 274. (NEW) The process of claim 271, wherein said cell is contained in an organism. --

Sub 25
08978634-1125
-- 275. (NEW) A multimeric composition comprising more than one component attached to a charged polymer, wherein said charged polymer is selected from a polycationic polymer, a polyionic polymer, a polynucleotide, a modified polynucleotide and a polynucleotide analog, or a combination of the foregoing. --

-- 276. (NEW) The multimeric composition of claim 275, wherein said component comprises a protein. --

Sub 26
-- 277. (NEW) The multimeric composition of claim 276, wherein said protein is selected from an antibody and an F(ab')₂ fragment, or both. --

-- 278. (NEW) The multimeric composition of claim 277, wherein said antibody comprises a polyclonal or monoclonal antibody. --

D
-- 279. (NEW) The multimeric composition of claim 277, wherein said antibody is further ^{Complexed} ~~complex~~ with a target comprising an enzyme.

* * * * *

BEST AVAILABLE COPY